|
CREST-I: Resperine, Gabapentin, or Lamotrigine vs. Placebo - 7 Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about CREST-I: Resperine, Gabapentin, or Lamotrigine vs. Placebo - 7 conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. CREST-I: Resperine, Gabapentin, or Lamotrigine vs. Placebo - 7 Clinical research trials and CREST-I: Resperine, Gabapentin, or Lamotrigine vs. Placebo - 7 healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as CREST-I: Resperine, Gabapentin, or Lamotrigine vs. Placebo - 7. CREST-I: Resperine, Gabapentin, or Lamotrigine vs. Placebo - 7 Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a CREST-I: Resperine, Gabapentin, or Lamotrigine vs. Placebo - 7 clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their CREST-I: Resperine, Gabapentin, or Lamotrigine vs. Placebo - 7 condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > CREST-I: Resperine, Gabapentin, or Lamotrigine vs. Placebo - 7  CREST-I: Resperine, Gabapentin, or Lamotrigine vs. Placebo - 7
CREST-I: Resperine, Gabapentin, or Lamotrigine vs. Placebo - 7
For Condition: Cocaine-Related Disorders
Status: Completed
Sponsor(s): National Institute on Drug Abuse (NIDA) ,
Synopsis: A Modified Placebo-Controlled Study for the Treatment of Cocaine Dependence Using Reserpine, Gabapentin, or Lamotrigine Versus an Unmatched Placebo Control
Details: Considerable progress in preclinical research has provided a basis for hypothesis driven clinical trials in cocaine dependence. A greater mechanistic understanding of both cocaine and many clinically approved medications has led to the identification of many promising medications for the treatment of cocaine dependence. For this reason NIDA has developed a CREST (Clinical Rapid Evaluation Screening Trial) protocol to provide a needed incremental medication screening step between preclinical research and full blown expensive Phase III pivotal trials. While patients receive manual based psychotherapy, three medications are screened compared to unmatched placebo in an eight-week, 60-subject, four cell design trial. Other important features of the CREST protocol include collecting baseline measurements over a two week period and analyzing primary outcome measures (quantitative urine toxicology and clinical global improvement scales) in terms of a composite score of overall individual patient improvement. The three medications being evaluated in this trial include reserpine, gabapentin and lamotrigine. Reserpine is being screened because of its well-known preclinical ability to functionally antagonize cocaine (by depleting neurochemicals elevated by cocaine). Gabapentin and lamotrigine are hypothesized to interfere with glutamatergic cocaine sensitization/kindling mechanisms relevant to addiction.
Eligibility:
Study Type: Interventional, Treatment, Placebo Control, Parallel Assignment
Minimum Age/Maximum Age: 18 Years/59 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: 1. Males and females, 18 to 59 years of age. 2. DSM-IV diagnosis of cocaine dependence as determine by a semi-structured clinical interview. 3. Subjects must have at least two cocaine-positive urines (BE level >300 ng/ml) during the two week screening phase of the study. 4. Subjects must have a self reported use of at least $100 worth of cocaine within the past 30 days. 5. Ability to provide written informed consent and to comply with all study procedures. 6. Women of child-bearing capacity must be using one of the following acceptable methods of birth-control: a. oral contraceptives, b. barrier (diaphragm or condom) with spermicide, c. intrauterine progesterone contraceptive system, d. levonorgestrel implant, e. medroxyprogesterone acetate contraceptive injection Exclusion Criteria: 1.Current dependence on any psychoactive substance other than cocaine, alcohol, or nicotine, physiological dependence on alcohol requiring medical detoxification. 2.Subjects requiring treatment for neurological or psychiatric disorders. 3. Subjects with any potentially life threatening or progressive medical illness other than addiction. 4.Subjects with a history of hypertension currently requiring treatment. 5.Subjects who have received a drug with known potential for toxicity to a major organ system within the month prior to entering treatment or who have been on any experimental medication within the past 60 days. 6.Fe males who are pregnant or lactating or having had three or more days of amenorrhea beyond the time of expected menses at the time of the first dose of study medication. 7.Subjects who have clinically significant abnormal laboratory values as determined by the principal investigator. 8.Subjects who have any disease of the gastrointestinal system, liver, or kidneys which could result in altered metabolism or excretion of the study medication. 9.Chronic therapy with any medication which could interact adversely with one of the medications under study. 10.Therapy with any of the opiate-substitutes (methadone, LAAM, buprenorphine) within 60 days of enrollment in this study. 11.Subjects with a seizure disorder or with a history of a seizure disorder other than childhood febrile seizures or alcohol withdrawal seizures. 12.Subjects with a history of major depression. 13.Patients with a history of rashes or other sensitivity reactions to reserpine, lamotrigine, or gabapentin. 14.Participant plans to receive psychosocial treatment external to that designated in the protocol during study participation. 15.Subjects with systolic blood pressure below 100 mm of Hg., or diastolic blood pressure below 60 mm of Hg., who are symptomatic as determined by the physician conducting the screening medical history and phy
Total Enrollment: 0
Location and Contact Information:
Overall Study Official:
EugeneSomoza, Principal Investigator, Cincinnati MDRU
Cincinnati MDRU
Cincinnati, Ohio, 45220
United States
Additional Information:
Study ID Numbers: NIDA-5-0012-7;
Study Start Date: November 1997
Record last reviewed: February 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00015106
Other Cocaine-Related Disorders Studies:
1. Cocaine-Methylphendidate Interaction Study - 4
2. Infusion Laboratory: Protocol 4 (Dihydrexidine) - 13
3. Pharmacotherapy and Intensive Treatment of Drug Abuse - 1
4. Human Dopamine Transported Imaging in Cocaine Abuse: 1 - 1
5. CREST-II: Tiagabine, Sertraline, or Donepezil vs. Unmatched Placebo - 9
Related Studies:
Other Cocaine-Related Disorders Clinical Trials
Other Ohio Clinical Trials
Other Cincinnati Clinical Trials
CREST-I: Resperine, Gabapentin, or Lamotrigine vs. Placebo - 7
|
|
|
|
|
|
|
|
